Vetr upgraded shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from a hold rating to a buy rating in a report published on Monday. The firm currently has $34.17 price target on the stock.
TEVA has been the topic of several other research reports. Oppenheimer Holdings, Inc. set a $43.00 price target on Teva Pharmaceutical Industries Limited and gave the company a buy rating in a research note on Thursday, April 6th. Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the company a hold rating in a research note on Thursday, June 22nd. Zacks Investment Research upgraded Teva Pharmaceutical Industries Limited from a sell rating to a hold rating in a research note on Monday, July 17th. Credit Suisse Group reiterated a buy rating and issued a $39.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, May 17th. Finally, BidaskClub upgraded Teva Pharmaceutical Industries Limited from a strong sell rating to a sell rating in a research note on Tuesday, June 13th. Fifteen investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $42.88.
Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 32.47 on Monday. Teva Pharmaceutical Industries Limited has a 12-month low of $27.59 and a 12-month high of $55.79. The company’s 50-day moving average is $31.54 and its 200-day moving average is $32.37. The company has a market capitalization of $32.99 billion, a price-to-earnings ratio of 416.28 and a beta of 0.46.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, hitting the consensus estimate of $1.06. The business had revenue of $5.63 billion during the quarter, compared to the consensus estimate of $5.69 billion. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The business’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period last year, the company earned $1.20 earnings per share. Analysts predict that Teva Pharmaceutical Industries Limited will post $4.75 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited (NYSE:TEVA) Upgraded to “Buy” at Vetr Inc.” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/07/25/teva-pharmaceutical-industries-limited-nyseteva-upgraded-to-buy-at-vetr-inc.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in TEVA. Guggenheim Capital LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 1.1% in the fourth quarter. Guggenheim Capital LLC now owns 40,276 shares of the company’s stock worth $1,460,000 after buying an additional 446 shares during the last quarter. Lincluden Management Ltd. increased its position in shares of Teva Pharmaceutical Industries Limited by 7.8% in the fourth quarter. Lincluden Management Ltd. now owns 58,854 shares of the company’s stock worth $2,133,000 after buying an additional 4,272 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Teva Pharmaceutical Industries Limited by 21.3% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,564,560 shares of the company’s stock worth $165,461,000 after buying an additional 801,106 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in shares of Teva Pharmaceutical Industries Limited by 150.7% in the fourth quarter. UBS Asset Management Americas Inc. now owns 2,004,760 shares of the company’s stock worth $72,672,000 after buying an additional 1,205,253 shares during the last quarter. Finally, HighPoint Advisor Group LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 19.3% in the fourth quarter. HighPoint Advisor Group LLC now owns 6,250 shares of the company’s stock worth $219,000 after buying an additional 1,010 shares during the last quarter. 56.19% of the stock is owned by institutional investors.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.
